Apyx Medical Corp
About Apyx Medical Corp
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $52.8M
- Net income
- -$11.2M
- Total assets
- $66.8M
- Market cap
- $187.2M
- Gross margin
- 62.5%
- Operating margin
- -12.2%
- Net margin
- -21.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $52.8M
- Cost of revenue
- $19.8M
- Gross profit
- $33.0M
- Operating expenses
- $39.5M
- Operating income
- -$6.4M
- Income tax
- $270.0K
- Net income
- -$11.1M
- EPS (basic)
- $-0.27
Balance sheet
- Total assets
- $66.8M
- Current assets
- $58.5M
- Total liabilities
- $52.0M
- Current liabilities
- $11.7M
- Shareholders’ equity
- $14.8M
Cash flow
- Operating cash flow
- -$8.0M
- Investing cash flow
- -$1.1M
- Financing cash flow
- $9.6M
- Net cash flow
- $465.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $187.2M
- Shares outstanding
- 39.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 6, 1994
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.2M in FY2025.
- Revenue grew 91% from FY2020 to FY2025.
- Gross margin of 62.5%, net margin -21.0%.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Apyx Medical Corp.
Write a review
News about Apyx Medical Corp
News & sentiment via Polygon.io
